
The drug regulation landscape in the United States is experiencing a pivotal transformation as the Food and Drug Administration (FDA) journeys toward integrating artificial intelligence (AI) into its core operations. This strategic move seeks to streamline the drug approval process, presenting both a technological opportunity and a regulatory challenge. At the heart of this initiative is the FDA’s ambitious timeline,










